Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Is Tricuspid Regurgitation after TAVR Significant?

Courtesy of Dr. Carlos Fava.

Severe or moderate mitral regurgitation is associated to worse evolution after TAVR. However, we should not forget the tricuspid valve that, even though not extensively researched, is also associated to a negative impact in its evolution.

Más coincidencias de las esperadas entre válvulas bicúspides y tricúspidesA meta-analysis of 12 studies with a total 41485 patients was carried out.

 

Early mortality (up to 6 months) was 1.8 times higher with severe or ≥moderate tricuspid regurgitation (OR, 1.80; 95% CI, 1.01 to 3.19; P=0.05). Between 6 and 30 months after TAVR, it was 1.9 times higher (HR/OR, 1.96; 95% CI, 1.35 to 2.85; P = 0.0004).


Read also: ¿Metformin to Treat Abdominal Aortic Aneurysms?


A second meta-analysis of 7 homogeneous studies was carried out and mortality between 6 and 30 months was 2.25 times higher (HR,2.25; 95% CI, 1.20–4.24; P= 0.01).

 

Conclusion

Significant tricuspid regurgitation (severe or ≥moderate) is associated to an approximate two-fold increase in early or mid-term all-cause mortality in patients with aortic stenosis undergoing TAVR.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation.

Reference: Hisato Takagi, et al. Catheter Cardiovasc Interv. 2018;1–8. DOI: 10.1002/ccd.27948.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...